CONFLITO DE INTERESSES DECLARADO POR TODOS OS PROFISSIONAIS DE SAÚDE CITADOS ACIMA
De acordo com a resolução 1931/2009 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro que recebi honorários da Gilead para esse evento.
REFERÊNCIAS
Abelman RO, Spring LM, Fell G, et al. Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): multi-institution experience and biomarker analysis. Abstract PS08-03. Presented at: the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, Texas.
Raghavendra S, Wang Z, Basset R, Tripathy D. Antibody-drug conjugates (ADCs) in breast cancer: real world analysis of outcomes. Abstract PS08-01. Presented at: the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, Texas.
Poumeaud F, Morisseau M, Cabel L, et al. Efficacy of sacituzumab-govitecan (SG) post trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study. Abstract PS08-02. Presented at: the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, Texas.
Huppert L, et al. Poster Presented at: 2023 SABCS; December 5-8; San Antonio, TX. 4. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Curr. Oncol. 2023, 30(12), 10211-10223; https://doi.org/10.3390/curroncol30120743
ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023; original Clinical Practice Guideline Ann Oncol 2021;32(12): 1475-1495;
Laura Ann Huppert, Reshma L. Mahtani et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies. Published at ASCO 2024.
